Chinook Therapeutics ( NASDAQ:KDNY – Get Rating ) had its price objective cut by HC Wainwright from $33.00 to $31.00 in a research report sent to investors on Tuesday morning, The Fly reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Chinook Therapeutics' Q1 2023 earnings at ($0.75) EPS, Q2 2023 earnings at ($0.76) EPS, Q3 2023 earnings at ($0.79) EPS, Q4 2023 earnings at ($0.77) EPS, FY2023 earnings at ($3.06) EPS, FY2024 earnings at ($3.54) EPS, FY2025 earnings at ($2.

https://www.dailypolitical.com/2023/03/03/hc-wainwright-cuts-chinook-therapeutics-nasdaqkdny-price-target-to-31-00.html

#dailypolitical